Lipase-Catalyzed Acylation and Deacylation Reactions of Pyridoxine, a Member of Vitamin- B_6 Group

by Alicia Baldessari*, Constanza P. Mangone, and Eduardo G. Gros

Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Pabellón 2, Ciudad Universitaria, 1428, Buenos Aires, Argentina

A series of acyloxy derivatives of pyridoxine (1) have been prepared by transesterification reactions of 1 and ethyl carboxylates, catalyzed by several lipases. Moreover, acetylated derivatives of 1 were selectively deacetylated by enzymatic catalysis in organic media.

Introduction. – Regioselective transformation of polyfunctional compounds is a challenging problem in organic synthesis, especially in case of a structure sensitive to acid, base, oxidation, or reduction, which limits the choice of reagents needed to accomplish a particular transformation. In recent years, lipases have become attractive as biocatalysts for regioselective reactions under mild conditions [1]. They can be used in a wide variety of organic solvents and do not require a coenzyme for activity. Although lipases are well-known as catalysts useful for transformations of natural products, such as carbohydrates [2], steroids [3], and terpenes [4], studies regarding their application on vitamin- B_6 compounds have not been reported. The vitamin- B_6 group consists of three phosphorylated and unphosphorylated vitamers: 5-hydroxy-6-methylpyridine-3,4-dimethanol named usually pyridoxine (1), 3-hydroxy-5-(hydroxymethyl)-2-methylpyridine-4-carbaldehyde, named pyridoxal (2), and 4-(aminomethyl)-5-hydroxy-6-methylpyridine-3-methanol, named pyridoxamine (3). They can be interconverted within the organism and show identical biological activity.

The compounds $1 - 3$ are essential cofactors to a large number of enzymes involved in the metabolism of amino acids $[5]$. Pyridoxine (1) is the main dietary and therapeutic form of the vitamin- B_6 group [6]. It can be used as antioxidant in cosmetic formulations [7] and food additives [8]. Less polar derivatives of the compounds $1-3$, such as esters, having better affinity for membrane lipids and increased skin penetration could be useful for the above mentioned purposes. These ester groups can be easily hydrolyzed in vivo providing the active molecule. Moreover, regioselective acylation products could be useful intermediates in synthetic pathway of vitamin- B_6 derivatives [9].

Selective esterification in a specific position of the pyridoxine (1) molecule is difficult because of three OH groups present. Attempts to acylate 1 under controlled conditions to furnish monoacylated compounds always resulted in a mixture of esters in which the desired compound could be isolated only after careful separation. Esterification in a specific position has been reported by chemical methods through several protection and deprotection steps [10], sometimes involving cyclic six- or sevenmembered ketals as intermediates [11] [12].

On the other hand, the application of the enzymatic approach to solve selectivity problems in acylation reactions by means of activated esters under the catalysis of enzymes in anhydrous organic solvents is well-known. Thus, in previous papers we have described this methodology for regio- and chemoselective acylation $[13 - 18]$ and deacylation $[19-21]$ of polyfunctional compounds using simple ethyl carboxylates, which are readily available and less expensive than the activated ones. In continuation of our work on application of lipases, we report in the present paper the results obtained in lipase-catalyzed acylation of pyridoxine (1) and alcoholysis of its acyl derivatives.

Results and Discussion. – We have prepared, under mild reaction conditions, monoand diacylated derivatives of pyridoxine (1) in a regiospecific manner and in moderateto-high yields. Different compounds have been obtained by acylation of the substrate or by alcoholysis of derivatives using lipases from several sources as catalysts: porcine pancreas lipase (PPL), lipozyme (LIP), Candida rugosa lipase (CRL), and Candida antarctica lipase (CAL).

1. Enzymatic Acylation. The enzyme-catalyzed acylation led, in a regiospecific way, to monoacylated derivatives with the acyl group exclusively suited in the 5-position of pyridine ring (see Scheme 1 and Table 1).

As in our previous work on enzymatic acylation $[13-19]$, we carried out acylations using ethyl carboxylates as acylating agents. To improve yields, we tested activated esters such as vinyl or isopropenyl carboxylates; however, with unsuccessful results. In case of 5a, AcOEt acted both as solvent and acylating agent. Although all four enzymes led to regiospecific results, CAL gave better yield in lower reaction time than the other three $(Table 1)$. To optimize the reaction conditions, we performed several experiments, varying reaction parameters such as temperature, enzyme/substrate relation (E/ S), and acylating agent/substrate ratio (A/S). Under standard conditions, reactions were conducted at 30 $^{\circ}$ with an E/S ratio of 2.5 and with an A/S ratio of 3.0 with acyl derivatives other than acetate. The efficiency of the tested enzymes in acylation

Enzyme	Acylating agent	Solvent	Time [h]	Product	Yield $[%]$
PPL	4a	AcOE	144	5а	54
LIP	4а	AcOE	96	5а	48
CRL	4a	AcOEt	96	5а	30
CAL	4а	AcOE	3	5а	74
CAL	4b	MeCN	24	5b	55
CAL	4b	acetone	24	5b	69
CAL	4c	MeCN	24	5с	53
CAL	4c	acetone	48	5с	64
CAL	4d	acetone	72	5d	57

Table 1. Lipase-Catalyzed Acylation of Pyridoxine $(1)^a$)

a) Reactions were performed under standard conditions.

reactions was variable and decreased with the increasing chain length of the acylating agent. Regioselectivity was retained in every case.

Solvent effects were also investigated. Due to its highly hydroxylated nature, pyridoxine (1) is only soluble in polar solvents. Nonpolar solvents such as hexane, toluene, and $CH₂Cl₂$ were not effective. MeCN and acetone turned out to be the best choice. Without enzymes, pyridoxine (1) did not react at all even using AcOEt, which afforded the best yield in the enzymatic reaction.

Monoacetyl derivative 5a was characterized as 5-(acetoxymethyl)-3-hydroxy-4- (hydroxymethyl)-2-methylpyridine on the basis of its spectroscopic properties. EI-MS Analysis showed a M^+ ion at m/z 211 indicating the presence of one Ac group. The HR-MS result was in agreement with the calculated value. The position of the AcOCH₂ group is established by ¹ H- and 13C-NMR spectra and confirmed by analysis of a COLOC spectrum. Complete 13C-NMR assignments were also performed by 2D-NMR experiments. HETCOR Spectra were used to assign unambiguously ^{13}C signals of $CH₂(8)$, $CH₂(9)$, and $C(6)¹$.

 $H-MMR$ Spectra of compounds 5b, 5c, and 5d were recorded in CDCl₃ instead of (D_6) DMSO for reasons of solubility. ¹H Chemical shifts of CH₂ groups of 5a in both solvents are given in *Table 2*.

Table 2. $H\text{-}NMR$ Chemical Shifts of CH₂ Groups of Pyridoxine (1) and 5-(Acetoxymethyl)-3-hydroxy-4- $(hydroxymethyl)-2-methylpyridine (5a)^a$)

Proton	$1((D_6)$ DMSO)	$5a$ (CDCl ₃)	5a ((D_6) DMSO)
CH ₂ (8)	4.76	4.99	4.70
CH ₂ (9)	4.49	5.01	5.11

^a) Chemical shifts (δ) in ppm. Solvents are indicated in parentheses.

1) Arbitrary numbering used for NMR assignments:

Substrate	Nucleophile	Solvent	Product	Yield $[\%]$
5a	EtOH	EtOH		99
6	EtOH	EtOH		80
6	EtOH	MeCN		78
6	BuOH	MeCN		79
6	Octan-1-ol	MeCN		80
8	EtOH	EtOH	9	69
8	BuOH	MeCN	9	68

Table 3. Lipase-Catalyzed Alcoholysis of the Acetyl Derivatives of Pyridoxine $(1)^a$)

For 5a, $\Delta\delta$ between both signals is 0.02 ppm in CDCl₃ and 0.41 in (D₆)DMSO. As this effect was retained in longer-chain monoacyl derivatives $5b - d$, it was possible to establish substitution position, which was additionally confirmed by COLOC spectrum.

2. Enzymatic Alcoholysis. The results of the alcoholysis of acetyl derivatives of pyridoxine (1) are presented in Table 3.

Lipase-catalyzed alcoholysis of triacetylated pyridoxine 6 gave, after 24 h, the 3,8 diacetylated derivative 7. After longer reaction periods, a mixture of 8-monoacetylated compound 9 and pyridoxine (1) was obtained. Melting point of 7 is in agreement with that reported in [22], and spectroscopic data confirmed the identity.

Compound 9 was also obtained by enzymatic treatment of 8,9-diacetylated pyridoxine 8. Data reported in [23] for 9 differ from that found in the present work. We determined a melting point of $104 - 105^\circ$ for the 4-(acetoxymethyl) derivative of pyridoxine while Korytnyk and Paul reported $155 - 157^{\circ}$, a value similar to the melting point of our 5-(acetoxymethyl) derivative 5a. There are also differences in the assignments of ¹H-NMR signals corresponding to $CH₂(8)$ and $CH₂(9)$. Table 4 shows chemical-shift values for these protons of compounds 1, 5a, 8, and 9, and those reported by Korytnyk and Paul for their compound 9.

Compound	CH ₂ (8)	CH ₂ (8) ^b	CH ₂ (9)	CH ₂ (9) ^b
	4.76		4.49	
5a	4.70		5.11	
9	5.15	5.15	4.51	4.78
8	5.13		5.10	

Table 4. ¹H-NMR Chemical Shifts of CH₂ Groups of Compounds **1**, 5a, 8, and 9^a)

According to our data, $CH₂(8)$ and $CH₂(9)$ protons of pyridoxine (1) resonate at 4.76 and 4.49 ppm, respectively. The diacetyl derivative $\boldsymbol{8}$ showed in its ¹H-NMR spectrum corresponding signals at 5.13 and 5.10 ppm, respectively, while corresponding signals in the $\mathrm{^1H\text{-}NMR}$ spectrum of 5a were at 4.70 and 5.11 ppm, respectively, Korytnyk and Paul reported absorptions at 5.15 and 4.78 ppm, respectively, for the mentioned protons, indicating that, in their product, the AcO group should by located at $C(9)$ instead of $C(8)$. We concluded, therefore, that the described 4-(acetoxymeth-

yl)-3-hydroxy-5-(hydroxymethyl)-2-methylpyridine of Korytnyk and Paul is indeed 5- (acetoxymethyl)-3-hydroxy-4-(hydroxymethyl)-2-methylpyridine (5a).

Alcoholysis reaction was conducted with several alcohols are nucleophiles, leading to similar results with all of them. Remarkable is the good performance exhibited by CAL in EtOH, a reagent which is not considered an appropriate solvent for enzymatic reactions carried out in organic medium.

Conclusion. – This work describes application of enzymes for the preparation of specifically acylated derivatives of pyridoxine. Lipases from different sources exhibited good performance as catalysts both in alcoholysis and acylation reactions. Candida *antarctica* lipase gave the best results in both reactions. By enzymatic acylation at $C(5)$ of the pyridine ring, various monoacylated derivatives $5a-d$ of pyridoxine (1) have been regiospecifically obtained; these products have not been previously reported early in literature.

All enzymatic reactions were performed under mild conditions, and ethyl carboxylates, which are considered inert as acylating agents in traditional chemical methodology, were used as acylating agents. Regiospecifity cannot be attained by conventional acylating agents, and polyacylated compounds are usually obtained.

Alcoholysis reactions yielded good results even with the short-chain alcohols such as EtOH. Based on current results and the general behavior displayed by CAL, it can be assumed that the active site of the enzyme acts only at $C(5)$ of the pyridine ring of pyridoxine both in acylation and alcoholysis reaction.

Experimental Part

General. Pyridoxine, lipase from Candida cylindracea (905 units/mg solid), and lipase (type II crude) from porcine pancreas (190 units/mg protein) were purchased from *Sigma Chemical Co.* Lipozyme (lipase IM-60 from Mucor miehei in the immobilized form on a microporous anion exchange resin) and Candida antarctica lipase (Novozym 435 (7400 PLU/g) acrylic-resin-supported lipase produced by a host organism Aspergillus oryzae, after transfer of the genetic coding for lipase B from Candida antarctica) were generous gifts of Novo Nordisk Bioindustrial Group. All enzymes were used 'straight from the bottle'. M.p.: Fisher-Johns apparatus, uncorrected. TLC: Merck silica gel 60F-254 aluminum sheets (0.2 mm thickness). Column chromatography (CC): Merck silica gel 60 (0.040 - 0.063 mm). IR Spectra: Nicolet-Magna-550-FT/IR spectrophotometer; in cm^{-1} . ¹H- and ¹³C-NMR Spectra: at 200 and 50 MHz, respectively, using a *Bruker AC-200* spectrometer; chemical shifts (δ) relative to Me₄Si; (D₆)DMSO, CDCl₃, and CD₃OD as solvents, assignments¹) based on COLOC and HETCOR spectra. EI-MS: at 70 eV using a TRIO-2 VG Masslab and Shimadzu QP-5000 spectrometers, in m/z (%). HR-MS: VG-ZAB BEQ instrument.

 $[5-Hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl/methyl$ Acetate (5a). To a soln. of 1 (200 mg, 1.2 mmol) in AcOEt (10 ml), 500 mg of CAL were added. The suspension was shaken (200 rpm) at 30° , and the progress of the reaction was monitored by TLC (AcOEt). After 3 h, the enzyme was filtered off, the solvent evaporated, and the crude residue purified by CC (AcOEt): 184 mg (74%) of 5a. White solid. M.p. $152-153^{\circ}$. IR (KBr): 3437, 2924, 2360, 1740, 1384, 1248, 1035. ¹H-NMR ((D₆)DMSO)¹): 7.91 (s, H – C(6)); 5.11 $(s, CH₂(9))$; 4.70 $(s, CH₂(8))$; 2.36 $(s, Me(7))$; 2.03 $(s, MeCO)$. ¹³C-NMR $((D₆)DMSO)¹$): 170.3 $(C(14))$; 149.7 $(C(3))$; 147.5 $(C(2))$; 140.4 $(C(6))$; 132.4 $(C(4))$; 128.0 $(C(5))$; 61.5 $(C(9))$; 56.3 $(C(8))$; 20.8 $(C(15))$; 19.6 $(C(7))$. EI-MS: 211 (15, M⁺), 193 (22, $[M-18]^+$), 151 (89), 123 (49), 106 (57), 94 (36), 43 (100). HR-MS: 211.0843 ($C_{10}H_{13}NO_3^+$; calc. 211.0845).

[5-Hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methyl Hexanoate (5b). To a soln. of 1 (200 mg, 1.2 mmol) in acetone (10 ml) containing ethyl hexanoate (0.5 ml, 3 mol-equiv.), 500 mg of CAL were added. The suspension was stirred (200 rpm) for 24 h at 30° , and the progress of reaction was monitored by TLC (AcOEt). The enzyme was filtered off, the mixture was concentrated in vacuo and purified by chromatography (silica gel; AcOEt: hexane 1:3): 217 mg (69%) of 5b. M.p. 78 - 79°. IR (KBr): 3450, 3197, 2952, 2874, 2646, 1747,

1391, 1255, 1163, 1042. ¹H-NMR (CDCl₃)¹): 7.88 (s, H – C(6)); 5.03 (s, CH₂(9)); 4.99 (s,CH₂(8)); 2.44 (s, Me(7)); 2.28 (t, J = 7.8, CH₂(15)); 1.27 (m, CH₂(16), CH₂(17), CH₂(18)); 0.87 (t, J = 6.9, Me(19)). ¹³C-NMR (CDCl₃/ CD₃OD ¹): 173.6 (C(14)); 151.6 (C(3)); 148.0 (C(2)); 139.2 (C(6)); 130.8 (C(4)); 126.2 (C(5)); 61.2 (C(9)); 59.6 (C(8)); 40.0 (C(15)); 31.0 (C(16)); 24.4 (C(17)); 22.0 (C(18)); 18.0 (C(7)); 13.6 (C(19)). EI-MS: 267 (3, (M^+) , 151(60), 123(28), 106(37), 94(22), 71(41), 60(27), 43(100). HR-MS: 267.1476 (C₁₄H₂₁NO₄⁺; calc. 267.1471).

[5-Hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methyl Decanoate (5c). As described for 5b, but using ethyl decanoate (0.7 ml, 3 mol-equiv.) as acylating agent and stirring the suspension for 48 h: 272 mg (64%) of **5c**. M.p. 79 – 80°. IR (KBr): 3430, 3166, 2924, 2852, 2717, 1733, 1384, 1255, 1163, 1048. ¹H-NMR (CDCl₃)¹): 7.88 $(s, H-C(6))$; 5.03 $(s, CH₂(9))$; 4.99 $(s, CH₂(8))$; 2.44 $(s, Me(7))$; 2.28 $(t, J = 7.8, CH₂(15))$; 1.25 $(m, CH₂(16) –$ $CH₂(22)$); 0.87 (t, J = 6.9, Me(23)). ¹³C-NMR (CDCl₃: CD₃OD)¹): 173.4 (C(14)); 151.5 (C(3)); 147.6 (C(2)); 138.7 (C(6)); 131.2 (C(4)); 126.4 (C(5)); 61.0 (C(9)); 59.0 (C(8)); 33.7 (C(15)); 31.4 (C(16)); 28.9 (C(17)); 28.8 (C(18)); 28.6 (C(19)); 24.5 (C(20)); 24.4 (C(21)); 22.2 (C(22)); 17.5 (C(7)); 13.4 (C(23)). EI-MS: 323 $(1, M^+), 151(77), 123(50), 106(43), 94(21), 71(30), 55(43), 43(100)$. HR-MS: 323.2097 $(C_{18}H_{29}NO₄⁺; calc.$ 323.2097).

[5-Hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methyl Tetradecanoate (5d). As described for 5b, but using ethyl tetradecanoate (0.9 ml, 3 mol-equiv.) as acylating agent and stirring the suspension for 72 h: 283 mg (57%) of 5d. M.p. 93–94°. IR (KBr): 3435, 3183, 2924, 2859, 2695, 1747, 1427, 1241, 1170, 1042. ¹H-NMR $(CDCl_3)^1$: 7.88 (s, H – C(6)); 5.03 (s, CH₂(9)); 4.99 (s, CH₂(8)); 2.44 (s, Me(7)); 2.28 (t, J = 7.8, CH₂(15)); 1.25 $(m, CH₂(16) - CH₂(26))$; 0.87 (t, J = 6.9, Me(27)). ¹³C-NMR (CDCl₃: CD₃OD)¹): 173.6 (C(14)); 151.6 (C(3)); 148.0 (C(2)); 139.2 (C(6)); 130.9 (C(4)); 126.3 (C(5)); 61.2 (C(9)); 59.6 (C(8)); 33.9 (C(15)); 31.7 (C(16)); 29.4, 29.2, 29.1, 29.0, 28.9 (C(17) to C(24)); 24.7 (C(22)); 22.5 (C(23)); 17.9 (C(7)); 13.8 (C(27)). EI-MS: 379 (1, (M^+) , 151(100), 123(55), 106(29), 94(13), 71(15), 57(41), 43(92). HR-MS: 379.2725 (C₂₂H₃₇NO₄⁺; calc. 379.2723).

4,5-Bis(acetoxymethyl)-2-methylpyridin-3-yl Acetate (6). A mixture of pyridoxine hydrochloride (450 mg, 2.2 mol-equiv.) and excess $Ac₂O$ in 1.5 ml of dry pyridine was kept overnight at r.t. The mixture was poured into ice-water to remove the excess reagents. The oily phase was separated and AcOEt (30 ml) was added. The resulting soln. was washed with aq. 1N NaOH soln. $(5 \times 20 \text{ ml})$ and H₂O $(2 \times 20 \text{ ml})$, dried (Na_2SO_4) , and evaporated *in vacuo*: 6 (370 mg, 57%). Viscous oil [24]. IR (film): 2970, 2942, 1763, 1602, 1370, 1225, 1041. ¹H-NMR (CDCl₃)¹): 8.37 (s, H – C(6)); 5.19 (s, CH₂(8)); 5.07 (s, CH₂(9)); 2.34 (s, Me(7)); 2.31 (s, Me(11)); 2.01 $(s, \text{Me}(15))$; 1.96 $(s, \text{Me}(13))$. ¹³C-NMR (CDCl₃)¹): 170.1 (C(12)); 170.0 (C(14)); 168.3 (C(10)); 153.0 (C(3)); 147.7 (C(6)); 144.5 (C(2)); 135.4 (C(4)); 129.3 (C(5)); 61.0 (C(9)); 56.7 (C(8)); 20.6 (C(13)); 20.3 (C(15), $C(11)$); 19.4 $(C(7))$. EI-MS: 295 (2, M⁺), 253 (35), 235 (26), 193 (66), 151 (100), 123 (62), 106 (51), 94 (19), 43 (79).

4-(Acetoxymethyl)-5-(hydroxymethyl)-2-methylpyridin-3-yl Acetate (7). To a soln. of 6 (200 mg, 0.68 mmol) in abs. EtOH (10 ml), 800 mg of CAL were added. The suspension was shaken (200 rpm) at 30° and the progress of reaction monitored by TLC (AcOEt). After 24 h, the enzyme was filtered off, the solvent evaporated, and the crude residue purified by chromatography (silica gel; AcOEt): 136 mg (80%) of 7. M.p. $88-89^{\circ}$ ([22]: $90-92^{\circ}$). IR (KBr): 3450, 3197, 2919, 1773, 1736, 1240, 1205, 1035. ¹H-NMR ((D₆)DMSO)¹): 8.37 (s, H-C(6)); 5.08 $(s, CH₂(8))$; 4.62 $(s, CH₂(9))$; 2.35 $(s, Me(7))$; 2.29 $(s, Me(11))$; 1.97 $(s, Me(13))$. ¹³C-NMR $((D₆)DMSO)¹$: 170.0 (C(12)); 168.8 (C(10)); 150.8 (C(3)); 146.0 (C(6)); 144.3 (C(2)); 135.3 (C(4)); 134.6 (C(5)); 58.5 (C(9)); 56.8 (C(8)); 20.4 (C(13)); 19.2 (C(11)); 17.4 (C(7)). EI-MS: 253 (2, M⁺), 211 (4), 193 (30), 151 (54), 123 (15), 94 (46), 43 (100).

 $3-Hydroxy-6-methylpyridine-3,4-dimethyl Diacetate (8)$. This compound was prepared according to [25] to give 4,5-bis(acetoxymethyl)-3-hydroxy-2-methylpyridine hydrochloride (1.69 g). The hydrochloride was dissolved in H₂O, and aq. NH₃ was added until precipitation of a white solid (pH 6.05). The white solid was filtered off and washed with H₂O to provide 8 (1.3 g, 70%). M.p. 97-98° ([26]: 99-100°). IR (KBr): 3458, 2945, 2375, 1755, 1740, 1384, 1234, 1042, 1027. ¹H-NMR ((D₆)DMSO)¹): 7.99 (s, H – C(6)); 5.13 $(s, CH₂(8))$; 5.10 $(s, CH₂(9))$; 2.40 $(s, Me(7))$; 2.01 $(s, Me(13), Me(15))$. ¹³C-NMR $((D₆)DMSO)¹$: 170.4 $(C(12))$; 170.2 $(C(14))$; 150.0 $(C(3))$; 148.3 $(C(2))$; 141.0 $(C(6))$; 129.3 $(C(4))$; 128.8 $(C(5))$; 61.5 $(C(9))$; 57.1 $(C(8))$; 20.7 $(C(15), C(13))$; 20.0 $(C(7))$. EI-MS: 253 (18, M⁺), 193 (44, [M – AcOH]⁺), 151 (76), 123 (61), 106 (62), 94 (32), 43 (100).

[3-Hydroxy-5-(hydroxymethyl)-2-methylpyridin-4-yl]methyl Acetate (9). This compound was prepared as described for 7, but using 200 mg (0.79 mmol) of 8 as substrate: 119 mg (69%) of 9. M.p. $104-105^{\circ}$ ([23]: 155 – 157°). IR (KBr): 3309, 2930, 2517, 2097, 1749, 1526, 1377, 1241, 1035. ¹H-NMR ((D₆)DMSO)¹): 7.97 (s, H – C(6));

5.15 (s, CH₂(8)); 4.51 (s, CH₂(9)); 2.38 (s, Me(7)); 2.00 (s, Me(13)). ¹³C-NMR ((D₆)DMSO)¹): 170.6 (C(12)); 149.8 (C(3)); 146.7 (C(2)); 139.6 (C(6)); 134.9 (C(4)); 127.9 (C(5)); 58.9 (C(9)); 57.1 (C(8)); 20.8 (C(13)); 19.9 $(C(7))$. EI-MS: 211 (12, M⁺), 193 (13, [M – H₂O]⁺), 151 (89), 123 (30), 106 (49), 94 (48), 43 (100).

We thank Novo-Nordisk for a generous gift of $Lipozyme^{TM}IM60$ (LIP) and SP 435 L (CAL), and UMYMFOR and LANAIS-EMAR for spectra. We are indebted to SECYT (UBA) and CONICET for partial financial support.

REFERENCES

- [1] A. Zaks, A. M. Klibanov, Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 3192.
- [2] L. Lay, L. Panza, S. Riva, M. Khitri, S. Tirendi, Carbohydr. Res. 1996, 29, 197.
- [3] S. Riva, Applied Biocatalysis, Marcel Dekker, Inc., New York, 1991.
- [4] F. M. Fonteyn, C. Blecker, G. Lognoy, M. Marlier, M. Severin, Biotechnol. Lett. 1994, 16, 693.
- [5] R. Pagani, R. Leoncini, L. Terzuoli, M. Pizzichini, E. Marinello, Biochim. Biophys. Acta 1994, 1204, 250.
- [6] M. L. Fonda, Alcohol. Clin. Exp. Res. 1993, 17, 1171.
- [7] R. Prasad, A. V. Lakshmi, M. S. Bamji. Biochem. Med. 1983, 30, 333.
- [8] E. M. Baker, J. E. Canham, W. T. Nunes, H. E. Sauberlich, M. E. McDowell, Am. J. Clin. Nutr. 1964, 15, 59.
- [9] D. Yang, Y. Shih, H. Liu, J. Org. Chem. 1991, 56, 2940.
- [10] L. Brown, G. A. Johnston, C. J. Suckling, P. J. Halling, R. H. Valivety, J. Chem. Soc., Perkin Trans. 1 1993, 2777.
- [11] W. J. Korytnyk, Org. Chem. 1962, 27, 3724.
- [12] W. Korytnyk, W. Wiedeman, J. Chem. Soc. 1962, 2531.
- [13] A. Baldessari, L. E. Iglesias, E. G. Gros, J. Chem. Res. 1992, 204.
- [14] A. Baldessari, L. E. Iglesias, E. G. Gros, J. Chem. Res. 1993, 382.
- [15] A. Baldessari, L. E. Iglesias, E. G. Gros, Biotechnol. Lett. 1994, 16, 479.
- [16] L. E. Iglesias, A. Baldessari, E. G. Gros, Bioorg. Med. Chem. Lett. 1996, 6, 853.
- [17] L. E. Iglesias, A. Baldessari, E. G. Gros, Biotechnol. Lett. 1997, 20, 275.
- [18] L. E. Iglesias, A. Baldessari, E. G. Gros, Anal. Asoc. Quím. Arg. 1998, 86, 63.
- [19] L. E. Iglesias, A. Baldessari, Anal. Asoc. Quím. Arg., in press.
- [20] A. Baldessari, M. S. Maier, E. G. Gros, *Tetrahedron Lett.* **1995**, 36, 4349.
- [21] A. Baldessari, A. C. Bruttomesso, E. G. Gros, Helv. Chim. Acta 1996, 79, 999.
- [22] E. Testa, F. Fava, Chimia 1957, 11, 307.
- [23] W. Korytnyk, W. Paul, J. Org. Chem. 1967, 32, 3791.
- [24] A. Itiba, K. Miti, Sci. Papers Inst. Phys. Chem. Res. 1938, 35, 73.
- [25] Societé Belge de l'Azote et des Produits Chimiques du Marly, Belg. 640,827, June 5, 1964, Appl. Dec. 5, 1963 (CA: 1965, 63, 587h).
- [26] S. Nakakura, Japan 70 31,666, (Cl. co7cd, A 61K, B01J) Oct. 13, 1970, Appl. Feb. 25, 1967 (CA: 1971, 74, 87855g).

Received September 7, 1998